Abstract：
BACKGROUND: Recent studies have shown a benefit of chest computed tomography (CT scan) in lung cancer screening. The COVID-19 pandemic has led to many chest CT scan performed on a large population. The objective of this study was to describe the incidence and characteristics of lung cancer detected on chest CT scan, outside the framework of a clinical trial, for a suspected or documented COVID-19 infection.
METHODS: We conducted a multicenter study, carried out from the analysis of data from the prospective COVID-19 database of the Clinical Data Warehouse of the Greater Paris University Hospitals (AP-HP). We identified the patients who had been diagnosed with a lung cancer, due to a chest CT scan done for a suspected or confirmed COVID-19 infection. The study period was limited to the first two epidemic lockdowns: (03/01/20 - 05/31/20) and (10/10/20 - 11/30/20).
RESULTS: Over the study period, 24 390 patients had at least one chest CT scan. Among them, 72 lung cancer diagnoses were made (incidence 0.30 %; median age 67.4 years old, 50.0 % current smokers, 55.6 % adenocarcinoma). Half of the lung cancer patients (n = 36) did not meet the National Lung Screening Trial inclusion criteria. Twenty-six patients (36.1 %) were diagnosed at an early stage, 25 (34.7 %) of whom received radical curative treatment. Twenty-six patients died during the follow-up (36.1 %) but none in early stages. The median overall survival in lung cancer patients was 693 days [532 - NA].
CONCLUSIONS: A large-scale chest CT scan strategy for suspected or documented COVID-19 infection has allowed a significant proportion of early-stage lung cancer diagnosis, all of which have benefited from curative treatment.
METHODS: We conducted a multicenter study, carried out from the analysis of data from the prospective COVID-19 database of the Clinical Data Warehouse of the Greater Paris University Hospitals (AP-HP). We identified the patients who had been diagnosed with a lung cancer, due to a chest CT scan done for a suspected or confirmed COVID-19 infection. The study period was limited to the first two epidemic lockdowns: (03/01/20 - 05/31/20) and (10/10/20 - 11/30/20).
RESULTS: Over the study period, 24 390 patients had at least one chest CT scan. Among them, 72 lung cancer diagnoses were made (incidence 0.30 %; median age 67.4 years old, 50.0 % current smokers, 55.6 % adenocarcinoma). Half of the lung cancer patients (n = 36) did not meet the National Lung Screening Trial inclusion criteria. Twenty-six patients (36.1 %) were diagnosed at an early stage, 25 (34.7 %) of whom received radical curative treatment. Twenty-six patients died during the follow-up (36.1 %) but none in early stages. The median overall survival in lung cancer patients was 693 days [532 - NA].
CONCLUSIONS: A large-scale chest CT scan strategy for suspected or documented COVID-19 infection has allowed a significant proportion of early-stage lung cancer diagnosis, all of which have benefited from curative treatment.
摘要：
背景：最近的研究表明胸部计算机断层扫描（CT扫描）在肺癌筛查中的益处。COVID-19大流行导致对大量人群进行了许多胸部CT扫描。这项研究的目的是描述胸部CT扫描发现的肺癌的发生率和特征，在临床试验的框架之外，怀疑或有记录的COVID-19感染。
方法：我们进行了一项多中心研究，对来自大巴黎大学医院（AP-HP）临床数据仓库的前瞻性COVID-19数据库的数据进行分析。我们确定了被诊断患有肺癌的患者，由于对疑似或确诊的COVID-19感染进行了胸部CT扫描。研究期间仅限于前两次流行病封锁：（03/01/20-05/31/20）和（10/10/20-11/30/20）。
结果：在研究期间，24390例患者至少进行了一次胸部CT扫描。其中,72例肺癌诊断（发病率为0.30％；中位年龄67.4岁，目前吸烟者占50.0%，55.6%腺癌)。一半的肺癌患者（n=36）不符合国家肺癌筛查试验纳入标准。26例(36.1%)患者在早期诊断,25例（34.7％）接受根治性治疗。26例患者在随访期间死亡（36.1％），但没有早期死亡。肺癌患者的中位总生存期为693天[532-NA]。
结论：对疑似或有记录的COVID-19感染的大规模胸部CT扫描策略允许相当比例的早期肺癌诊断，所有这些都受益于治愈性治疗。
方法：我们进行了一项多中心研究，对来自大巴黎大学医院（AP-HP）临床数据仓库的前瞻性COVID-19数据库的数据进行分析。我们确定了被诊断患有肺癌的患者，由于对疑似或确诊的COVID-19感染进行了胸部CT扫描。研究期间仅限于前两次流行病封锁：（03/01/20-05/31/20）和（10/10/20-11/30/20）。
结果：在研究期间，24390例患者至少进行了一次胸部CT扫描。其中,72例肺癌诊断（发病率为0.30％；中位年龄67.4岁，目前吸烟者占50.0%，55.6%腺癌)。一半的肺癌患者（n=36）不符合国家肺癌筛查试验纳入标准。26例(36.1%)患者在早期诊断,25例（34.7％）接受根治性治疗。26例患者在随访期间死亡（36.1％），但没有早期死亡。肺癌患者的中位总生存期为693天[532-NA]。
结论：对疑似或有记录的COVID-19感染的大规模胸部CT扫描策略允许相当比例的早期肺癌诊断，所有这些都受益于治愈性治疗。
